Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | nmda type glutamate receptor | 0.2261 | 0.6545 | 0.6371 |
Loa Loa (eye worm) | integrin alpha pat-2 | 0.0704 | 0.1188 | 1 |
Echinococcus multilocularis | Glutamate receptor, ionotropic kainate 3 | 0.1173 | 0.2803 | 0.244 |
Echinococcus multilocularis | glutamate receptor NMDA | 0.2092 | 0.5964 | 0.5761 |
Treponema pallidum | amino acid ABC transporter, periplasmic binding protein | 0.0844 | 0.167 | 0.5 |
Brugia malayi | Integrin alpha pat-2 precursor | 0.0457 | 0.0337 | 0.5 |
Chlamydia trachomatis | arginine ABC transporter substrate-binding protein ArtJ | 0.0844 | 0.167 | 0.5 |
Schistosoma mansoni | family A2 unassigned peptidase (A02 family) | 0.0539 | 0.0623 | 0.033 |
Mycobacterium tuberculosis | Probable glutamine-binding lipoprotein GlnH (GLNBP) | 0.0844 | 0.167 | 0.5 |
Mycobacterium ulcerans | glutamine-binding lipoprotein GlnH | 0.0844 | 0.167 | 0.5 |
Echinococcus granulosus | nmda type glutamate receptor | 0.2261 | 0.6545 | 0.6371 |
Echinococcus multilocularis | nmda type glutamate receptor | 0.3266 | 1 | 1 |
Schistosoma mansoni | glutamate receptor NMDA | 0.259 | 0.7678 | 0.8501 |
Schistosoma mansoni | intracisternal A-particle retropepsin (A02 family) | 0.2967 | 0.8972 | 1 |
Treponema pallidum | amino acid ABC transporter, periplasmic binding protein (hisJ) | 0.0844 | 0.167 | 0.5 |
Echinococcus granulosus | glutamate receptor NMDA | 0.2092 | 0.5964 | 0.5761 |
Chlamydia trachomatis | glutamine binding protein | 0.0844 | 0.167 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | 0 nM | Concentration required for 50% growth inhibition of NaK activity in porcine cerebral cortex; (not determined) | ChEMBL. | 15689169 |
IC50 (functional) | = 4 nM | Concentration required for 50% growth inhibition of human Hs 683 cancer cell lines after 3 days of culture | ChEMBL. | 15689169 |
IC50 (functional) | = 4 nM | Concentration required for 50% growth inhibition of human A549 cancer cell lines after 3 days of culture | ChEMBL. | 15689169 |
IC50 (functional) | = 4 nM | Concentration required for 50% growth inhibition of human A549 cancer cell lines after 3 days of culture | ChEMBL. | 15689169 |
IC50 (functional) | = 18 nM | Concentration required for 50% growth inhibition of human LoVo cancer cell lines after 3 days of culture | ChEMBL. | 15689169 |
IC50 (functional) | = 18 nM | Concentration required for 50% growth inhibition of human LoVo cancer cell lines after 3 days of culture | ChEMBL. | 15689169 |
IC50 (functional) | = 38 nM | Concentration required for 50% growth inhibition of human U373 cancer cell lines after 3 days of culture | ChEMBL. | 15689169 |
IC50 (functional) | = 38 nM | Concentration required for 50% growth inhibition of human U373 cancer cell lines after 3 days of culture | ChEMBL. | 15689169 |
IC50 (functional) | = 44 nM | Concentration required for 50% growth inhibition of human HCT-15 cancer cell lines after 3 days of culture | ChEMBL. | 15689169 |
IC50 (functional) | = 44 nM | Concentration required for 50% growth inhibition of human HCT-15 cancer cell lines after 3 days of culture | ChEMBL. | 15689169 |
MTD (functional) | = 80 mg kg-1 | Maximum tolerated dose of the compound was determined after intraperitoneal administration in mouse (period of 28 days) | ChEMBL. | 15689169 |
MTD (functional) | = 80 mg kg-1 | Maximum tolerated dose of the compound was determined after intraperitoneal administration in mouse (period of 28 days) | ChEMBL. | 15689169 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 | 15689169 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.